Haematology

News

Gilead drops CD47 drug magrolimab for blood cancers

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical t

News

GSK backs up its Blenrep rehab bid with survival data

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it fail

News

Takeda grabs late-stage haematology drug from Protagonist

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics.

News

Novartis calls time on Tim3 drug sabatolimab in MDS

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.

News

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or

News

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo

Gilead drops CD47 drug magrolimab for blood cancers

GSK backs up its Blenrep rehab bid with survival data

Takeda grabs late-stage haematology drug from Protagonist

Novartis calls time on Tim3 drug sabatolimab in MDS

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Haematology

Editor's Picks